Summary of Clinical Use

Phase 2 evaluation in a 12 week study has demonstrated the clinical efficacy effected by inhibiting macrophage activity via targeting of GM-CSF in patients with rheumatoid arthritis [5].

Mechanism Of Action and Pharmacodynamic Effects

GM-CSF (CSF2) is a pro-inflammatory cytokine that is over-produced in many autoimmune and chronic inflammatory human diseases. Namilumab binds to this cytokine, neutralises its activity and mediates a reduction in inflammation in vitro and in preclinical in vivo models [2].